Cogent Biosciences Inc - Asset Resilience Ratio
Cogent Biosciences Inc (COGT) has an Asset Resilience Ratio of 62.79% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cogent Biosciences Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Cogent Biosciences Inc's Asset Resilience Ratio has changed over time. See what is Cogent Biosciences Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cogent Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cogent Biosciences Inc (COGT) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $588.75 Million | 62.79% |
| Total Liquid Assets | $588.75 Million | 62.79% |
Asset Resilience Insights
- Very High Liquidity: Cogent Biosciences Inc maintains exceptional liquid asset reserves at 62.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cogent Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Cogent Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Cogent Biosciences Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Cogent Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.79% | $588.75 Million | $937.61 Million | +5.18pp |
| 2024-12-31 | 57.61% | $188.91 Million | $327.90 Million | -10.18pp |
| 2023-12-31 | 67.79% | $212.48 Million | $313.44 Million | +28.10pp |
| 2022-12-31 | 39.69% | $119.39 Million | $300.81 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $232.09 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $49.42 Million | -- |
| 2018-12-31 | 26.68% | $22.92 Million | $85.93 Million | +0.84pp |
| 2017-12-31 | 25.84% | $12.69 Million | $49.12 Million | -10.15pp |
| 2016-12-31 | 35.99% | $27.19 Million | $75.55 Million | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more